A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- Registration Number
- NCT04242446
- Lead Sponsor
- UCB Biopharma SRL
- Brief Summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 505
-
Participant must be at least 18 years of age, at the time of signing the informed consent. If a study participant is under the local age of consent and is at least 18 years of age, written informed consent will be obtained from both the study participant and the legal representative
-
Study participants must have a diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 6 months prior to the Baseline visit
-
Study participant must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits
-
Study participant must have moderate to severe HS defined as a total of ≥5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits
-
Study participant must have had an inadequate response to a course of a systemic antibiotic for treatment of HS as assessed by the Investigator through study participant interview and review of medical history
-
A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
- A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 20 weeks after the last dose of investigational medicinal product (IMP)
- Draining tunnel count of >20 at the Baseline Visit
- Any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the Investigator, interfere with the assessment of hidradenitis suppurativa (HS)
- Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD)
- Primary immunosuppressive condition, including taking immunosuppressive therapy following an organ transplant, or has had a splenectomy
- Female who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)
- Active infection or history of certain infection(s)
- Active tuberculosis (TB) infection, latent TB infection, high risk of exposure to TB infection, current or history of nontuberculous mycobacterium (NTM) infection
- Concurrent malignancy. Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured
- History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
- Known hypersensitivity to any components of bimekizumab or comparative drugs as stated in this protocol
- Concomitant and prior medication restrictions
- Myocardial infarction or stroke within the 6 months prior to the Screening Visit
- Study participant has the presence of active suicidal ideation, or positive suicide behavior using the "Screening" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
- Presence of moderately severe major depression or severe major depression
- Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Bimekizumab dosing regimen 3 Bimekizumab Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period. Bimekizumab dosing regimen 1 Bimekizumab Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period. Placebo Group Placebo Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period. Bimekizumab dosing regimen 2 Bimekizumab Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period. Placebo Group Bimekizumab Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 Week 16 HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 Week 16 HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16 Baseline, Week 16 The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.
Absolute Change From Baseline in Worst Skin Pain Score at Week 16 Baseline, Week 16 Absolute change from Baseline in Worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.
Percentage of Participants Achieving Worst Skin Pain Response at Week 16 Week 16 Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentage of participants shown do not account for model effects using logistic regression model.
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study From Baseline (Day 1) until Safety Follow-Up (up to Week 71) An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up \[SFU\] period).
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study From Baseline (Day 1) until Safety Follow-Up (up to Week 71) A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study From Baseline (Day 1) until Safety Follow-Up (up to Week 71) An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.
Trial Locations
- Locations (88)
Hs0003 50270
🇺🇸Seattle, Washington, United States
Hs0003 50149
🇺🇸San Antonio, Texas, United States
Hs0003 50175
🇺🇸Phoenix, Arizona, United States
Hs0003 50140
🇺🇸Birmingham, Alabama, United States
Hs0003 50161
🇺🇸Los Angeles, California, United States
Hs0003 50205
🇺🇸North Miami Beach, Florida, United States
Hs0003 50220
🇺🇸San Diego, California, United States
Hs0003 50280
🇺🇸Watkinsville, Georgia, United States
Hs0003 50210
🇺🇸Atlanta, Georgia, United States
Hs0003 50425
🇺🇸Murray, Kentucky, United States
Hs0003 50146
🇺🇸Boston, Massachusetts, United States
Hs0003 50208
🇺🇸Las Vegas, Nevada, United States
Hs0003 50177
🇺🇸Cincinnati, Ohio, United States
Hs0003 50235
🇺🇸New York, New York, United States
Hs0003 50151
🇺🇸Chapel Hill, North Carolina, United States
Hs0003 50138
🇺🇸Columbus, Ohio, United States
Hs0003 50147
🇺🇸Hershey, Pennsylvania, United States
Hs0003 50180
🇺🇸Providence, Rhode Island, United States
Hs0003 50204
🇺🇸Tulsa, Oklahoma, United States
Hs0003 50166
🇺🇸Dallas, Texas, United States
Hs0003 50142
🇺🇸Nashville, Tennessee, United States
Hs0003 50201
🇺🇸Arlington, Texas, United States
Hs0003 30015
🇦🇺Campbelltown, Australia
Hs0003 30011
🇦🇺East Melbourne, Australia
Hs0003 30017
🇦🇺Kogarah, Australia
Hs0003 50233
🇨🇦Barrie, Canada
Hs0003 50192
🇨🇦Saskatoon, Canada
Hs0003 50190
🇨🇦Richmond Hill, Canada
Hs0003 50133
🇨🇦Surrey, Canada
Hs0003 40197
🇫🇷Amiens Cedex 1, France
Hs0003 40285
🇫🇷Toulon, France
Hs0003 40325
🇩🇪Berlin, Germany
Hs0003 40246
🇫🇷Saint Mandé, France
Hs0003 40327
🇩🇪Bonn, Germany
Hs0003 40248
🇩🇪Bochum, Germany
Hs0003 40324
🇩🇪Dresden, Germany
Hs0003 40357
🇩🇪Magdeburg, Germany
Hs0003 40249
🇩🇪Kiel, Germany
Hs0003 40174
🇩🇪Mainz, Germany
Hs0003 40288
🇩🇪Darmstadt, Germany
Hs0003 40323
🇩🇪München, Germany
Hs0003 40177
🇩🇪Münster, Germany
Hs0003 40253
🇬🇷Athens, Greece
Hs0003 40257
🇮🇹Roma, Italy
Hs0003 40261
🇮🇹Catania, Italy
Hs0003 40263
🇮🇹Roma, Italy
Hs0003 40331
🇮🇹Terracina, Italy
Hs0003 40330
🇮🇹Torino, Italy
Hs0003 40258
🇮🇹Rozzano, Italy
Hs0003 40351
🇳🇱Breda, Netherlands
Hs0003 40294
🇪🇸Las Palmas de Gran Canaria, Spain
Hs0003 40295
🇪🇸Pontevedra, Spain
Hs0003 40332
🇳🇴Trondheim, Norway
Hs0003 40266
🇪🇸Badalona, Spain
Hs0003 40230
🇪🇸Valencia, Spain
Hs0003 40049
🇪🇸Sevilla, Spain
Hs0003 40337
🇨🇭Bern, Switzerland
Hs0003 40053
🇹🇷Ankara, Turkey
Hs0003 40273
🇹🇷Gaziantep, Turkey
Hs0003 40272
🇹🇷Istanbul, Turkey
Hs0003 40270
🇹🇷Antalya, Turkey
Hs0003 40050
🇹🇷Istanbul, Turkey
Hs0003 40271
🇹🇷İ̇zmir, Turkey
Hs0003 30016
🇦🇺Carlton, Australia
Hs0003 50141
🇺🇸Tampa, Florida, United States
Hs0003 50008
🇺🇸Johnston, Rhode Island, United States
Hs0003 50198
🇺🇸Beverly, Massachusetts, United States
Hs0003 50153
🇺🇸Ormond Beach, Florida, United States
Hs0003 50194
🇺🇸Omaha, Nebraska, United States
Hs0003 50137
🇺🇸East Windsor, New Jersey, United States
Hs0003 30012
🇦🇺Woolloongabba, Australia
Hs0003 40127
🇩🇰Aarhus N, Denmark
Hs0003 50173
🇨🇦St. John's, Canada
Hs0003 40342
🇫🇷Angers, France
Hs0003 40318
🇫🇷Rouen Cedex, France
Hs0003 40132
🇫🇷Nice, France
Hs0003 40355
🇫🇷Le Mans, France
Hs0003 20089
🇮🇱Haifa, Israel
Hs0003 40406
🇨🇭Genève, Switzerland
Hs0003 40121
🇧🇪Bruxelles, Belgium
Hs0003 40002
🇧🇪Leuven, Belgium
Hs0003 40292
🇳🇱Groningen, Netherlands
Hs0003 40004
🇧🇪Brussels, Belgium
Hs0003 40264
🇳🇱Rotterdam, Netherlands
Hs0003 20088
🇮🇱Tel Aviv, Israel
Hs0003 40060
🇧🇪Liege, Belgium
Hs0003 40251
🇬🇷Athens, Greece
Hs0003 40252
🇬🇷Thessaloniki, Greece